<DOC>
	<DOCNO>NCT01206608</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority SKY0402 conventional , commercially-available bupivacaine HCl respect duration analgesic effect achieve single local administration study drug .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Single Dose SKY0402 Subjects Undergoing Augmentation Mammoplasty</brief_title>
	<detailed_description>This Phase 2 , parallel-group , active-control , randomize , double-blind study conduct evaluate single local administration low dose high dose SKY0402 compare 75 mg bupivacaine HCl ( i.e. , MarcaineÂ® 0.5 % ) woman undergo bilateral , cosmetic , sub-muscular , augmentation mammoplasty general anesthesia . Each subject serve control . A total 40 subject randomize 1:1 ratio receive one follow regimen : - Low-dose SKY0402 one side Marcaine 75 mg contralateral side . - Mid-dose SKY0402 one side Marcaine 75 mg contralateral side . Study drug administer locally breast implant pocket end surgery . After surgery , subject receive standard treatment acetaminophen 1000 mg three time daily rescue analgesia immediate-release oxycodone , need , breakthrough pain . Assessments postoperative pain conduct 96 hour . Safety assessment conduct include monitor local systemic adverse event ( AEs ) .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Subjects meet follow criterion eligible inclusion study : 1 . Women , 1840 year age Screening Visit . 2 . Postmenopausal , surgically sterile , willing use acceptable mean contraception least 30 day surgery include follow : hormonal contraceptive ( e.g. , oral , injectable , implantable start least 30 day study drug administration ) , effective doublebarrier method ( e.g. , condom spermicide ) , intrauterine device , lifestyle personal choice abstinence , nonheterosexual lifestyle , strictly monogamous relationship partner vasectomy . 3 . Scheduled undergo primary , bilateral , submuscular , augmentation mammoplasty general anesthesia . 4 . American Society Anesthesiology ( ASA ) Physical Class 13 . 5 . Able willing comply study visit procedure . 6 . Able speak , read , understand language ICF , study questionnaire , instrument use collect subjectreported outcome , order enable accurate appropriate response pain scale require study assessment . 7 . Willing capable provide write informed consent . Subjects eligible study meet follow criterion : 1 . Pregnancy , nursing , plan become pregnant study within one month study drug administration . 2 . Body weight less 50 kilogram . 3 . History hypersensitivity idiosyncratic reaction amidetype local anesthetic opioid medication . 4 . Administration investigational product within 30 day 5 elimination halflives investigational product , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study . 5 . History , suspect , know addiction abuse illicit drug ( ) , prescription medicine ( ) , alcohol within past 2 year . 6 . Uncontrolled anxiety , schizophrenia , psychiatric disorder , opinion Investigator , may interfere study assessment compliance . 7 . Significant medical condition laboratory result , opinion Investigator , indicate increase vulnerability study drug procedure , expose subject unreasonable risk result participate clinical trial ( e.g. , severe hepatic insufficiency , hypotension , heart block , severely impaired cardiac function ) . In addition , subject ineligible receive study drug meet follow criterion surgery : 8 . Any clinically significant event condition uncover surgery ( e.g. , excessive bleeding , acute sepsis ) might render subject medically unstable complicate subject 's postoperative course .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Breast augmentation</keyword>
	<keyword>Pain</keyword>
	<keyword>Analgesia</keyword>
</DOC>